European multicenter study on propionyl-L-carnitine in intermittent claudication

Journal of the American College of Cardiology

Volumn 34, Issue 5, 1999, Pages 1618-1624

  Brevetti, Gregorio ^a   Diehm, Curt ^b   Lambert, David ^c  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b Klinikum Karlsbad Langensteinbach   (Germany)

^c FREEMAN HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PROPIONYLCARNITINE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; ELECTROCARDIOGRAM; FUNCTIONAL DISEASE; HUMAN; HUMAN CELL; HUMAN TISSUE; INTERMITTENT CLAUDICATION; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PHYSICAL DISABILITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREADMILL; WALKING;

CARDIOTONIC AGENTS; CARNITINE; DOUBLE-BLIND METHOD; EUROPE; FEMALE; HUMANS; INTERMITTENT CLAUDICATION; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 0033230534     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(99)00373-3     Document Type: Article

References (25)

1. Hiatt WR, Nawaz D, Brass EP. Carnitine metabolism during exercise in patients with peripheral vascular disease. J Appl Physiol 1987;62:2383-7.
2. Brevetti G, Angelini C, Rosa M, et al. Muscle carnitine deficiency in patients with severe peripheral vascular disease. Circulation 1991;84:1490-5.
3. Hiatt WR, Wolfel EE, Regensteiner JG. Brass EP. Skeletal muscle carnitine metabolism in patients with unilateral peripheral arterial disease. J Appl Physiol 1992;73:346-53.
4. Brevetti G, di Lisa F, Perna S, et al. Carnitine-related alterations in patients with intermittent claudication. Indication for a focused carnitine therapy. Circulation 1996;93:1685-9.
5. Brevetti G, Chiariello M, Ferulano G, et al. Increases in walking distance in patients with peripheral vascular disease treated with L-carmtine: a double-blind, cross-over study. Circulation 1988;77:767-73.
6. Siliprandi N, Di Lisa F, Menabò R. Propionyl-L-carnitine: biochemical significance and possible role in cardiac metabolism. Cardiovasc Drugs Ther 1991;5:11-16.
7. Brevetti G, Perna S, Sabba C, et al. Superiority of L-propionyl carnitine vs L-carnitine in improving walking capacity in patients with peripheral vascular disease. An acute, intravenous, double-blind, crossover study. Eur Heart J 1992;13:251-5.
8. Brevetti G, Perna S, Sabbà C, et al. Propionyl-L-carnitine m intermittent claudication: double-blind, placebo-controlled, dose titration, multicenter study. J Am Coll Cardiol 1995;26:1411-6.
9. Brevetti G, Perna S, Sabbà C, et al. Effect of propionyl-L-carnitine on quality of life in intermittent claudication. Am J Cardiol 1997;79:777-80.
10. Jaeschke R, Guyatt GH. How to develop and validate a new quality of life instrument. In: Spilken B, ed. Quality of Life Assessments in Clinical Trials. New York: Raven Press, 1990:45-57.
11. Mantel N. Chi-square tests with one degree of freedom: extension of the Mantel-Haenszel procedure. J Am Stat Assoc 1963;58:690-700.
12. Hiatt WR, Regensteiner JG, Wolfel EE, et al. Carnitine and acylcarnitine metabolism during exercise in humans. Dependence on skeletal muscle metabolic state. J Clin Invest 1989;84:1167-73.
13. Arfiderson B, Karlson J, Dahllof AG, et al. The impact of intermittent claudication on quality of life evaluated by the Sickness Impact Profile Technique. Eur J Clin Invest 1993;23:741-5.
14. Hiatt WR. Current and future drug therapies for claudication. Vase Med 1997;2:257-62.
15. Cameron HA, Waller PC, Ramsay LE. Drug treatment of intermittent claudication: a critical analysis of the methods and findings of published clinical trials, 1965-1985. Br J Clin Pharmacol 1988;26:569-76.
16. Radack K, Wyderski RJ. Conservative management of intermittent claudication. Ann Intern Med 1990;113:135-46.
17. Bevan EG, Waller PC, Ramsay LE. Pharmacological approaches to the treatment of intermittent claudication. Drugs Aging 1992;2:125-36.
18. Hurny C, Berhard J, Coates A, et al. Responsiveness of a simgle-item indicator versus a multi-item scale: assessment of emotional well-being in an internation adjuvant breast cancer trial. Med Care 1996;34:234-48.
19. Ramsey EW, Miller PD, Parsons K. A novel transurethral microwave thermal ablation system to tread benign prostatic hyperplasia: results of a prospective multicenter clinical trial. J Urol 1997;158:112-8.
20. Berhard J, Peterson HF, Coates A, et al. Quality of life assessment in International Breast Cancer Study Group (IBCSG) trials: practical issues and factors associated with missing data. Stat Med 1998;17:587.
21. Cronenwett JL, Warner KG, Zelenock GB, et al. Intermittent claudication. Current results of nonoperative management. Arch Surg 1984;119:430-6.
22. O'Riordain DS, O'Donnell JA. Realistic expectations for the patient with intermittent claudication. Br J Surg 1991;78:861-3.
23. Brevetti G, Martone VD, Perna S, et al. Intermittent claudication and risk of cardiovascular events. Angiology 1998;10:843-8.
24. Bloor K. Natural history of arteriosclerosis of the lower extremities. Ann R Coll Surg Engl 1961;28:36-52.
25. Boyd AM. The natural course of arteriosclerosis of the lower extremities. Proc R Soc Med 1962;55:10-4.